SCHEMBL6070964

SCHEMBL6070964

Nc1ccc2[nH]c3c(c2c1)CCCC3=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.68
ALDH1A1 P00352 6/20 0.68
LMNA P02545 5/20 0.68
MAPT P10636 5/20 0.68
HPGD P15428 3/20 0.68
GAA P10253 1/20 0.68
MAPK1 P28482 1/20 0.68
HSD17B10 Q99714 5/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
POLB P06746 1/20 0.55
ALOX15 P16050 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CYP1A1 P04798 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP1B1 Q16678 1/20 0.49
CCNB2 O95067 1/20 0.49
CDK1 P06493 1/20 0.49
CCNB1 P14635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4234216 0.81 KDM4E (0.68) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL4031072 0.81 KDM4E (1.00) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL2360729 0.81 LMNA (1.00) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL15264704 0.81 KDM4E (0.68) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL4022842 0.81 KDM4E (1.00) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL31721163 0.81 LMNA (1.00) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL9920628 0.81 PRKD1 (0.71) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL10172991 0.79 CCNB2 (0.56) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL29666273 0.78 HSD17B10 (1.00) KDM4EALDH1A1LMNAMAPTHPGD
SCHEMBL4021839 0.78 HSD17B10 (1.00) KDM4EALDH1A1LMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 KDM4E 1799/4885ALDH1A1 4446/4885LMNA 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.